BRPI0414793A - uso do fator anti-secretor - Google Patents

uso do fator anti-secretor

Info

Publication number
BRPI0414793A
BRPI0414793A BRPI0414793-6A BRPI0414793A BRPI0414793A BR PI0414793 A BRPI0414793 A BR PI0414793A BR PI0414793 A BRPI0414793 A BR PI0414793A BR PI0414793 A BRPI0414793 A BR PI0414793A
Authority
BR
Brazil
Prior art keywords
cell
condition
stem cell
disease
progenitor cell
Prior art date
Application number
BRPI0414793-6A
Other languages
English (en)
Inventor
Hans-Arne Hansson
Eva Jennische
Stefan Lange
Ivar Lonnroth
Peter Eriksson
Anders Persson
Original Assignee
Faktor Ab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faktor Ab As filed Critical Faktor Ab As
Publication of BRPI0414793A publication Critical patent/BRPI0414793A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)

Abstract

"USO DO FATOR ANTI-SECRETOR". A presente invenção refere-se ao uso de uma proteína anti-secretora ou homólogos da mesma que possuem as mesmas propriedades ou certos fragmentos dos mesmos na produção de um medicamento ou de um alimento medicinal para induzir maior recuperação de tecido nervoso danificado ou doente, proliferação, apoptose, diferenciação e/ou migração de uma célula-tronco embrionária, célula-tronco adulta, célula progenitora e/ou uma célula derivada de uma célula-tronco ou célula progenitora, para o tratamento de uma condição caracterizada por ou associada com a perda e/ou o ganho de células. Em uma modalidade preferida, a condição é uma neurotrauma ou uma condição ou doença do SNC e/ou do SNP e/ou do SNA, por exemplo, a doença de Alzheimer.
BRPI0414793-6A 2003-09-26 2004-09-24 uso do fator anti-secretor BRPI0414793A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322645.3A GB0322645D0 (en) 2003-09-26 2003-09-26 Use of antisecretory factor peptides
PCT/SE2004/001369 WO2005030246A1 (en) 2003-09-26 2004-09-24 Novel use of antisecretory factor

Publications (1)

Publication Number Publication Date
BRPI0414793A true BRPI0414793A (pt) 2006-11-21

Family

ID=29286947

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414793-6A BRPI0414793A (pt) 2003-09-26 2004-09-24 uso do fator anti-secretor

Country Status (18)

Country Link
US (2) US20070009575A1 (pt)
EP (1) EP1734989B1 (pt)
JP (1) JP4943847B2 (pt)
KR (1) KR101159858B1 (pt)
CN (2) CN103028110B (pt)
AT (1) ATE550030T1 (pt)
AU (1) AU2004275682B2 (pt)
BR (1) BRPI0414793A (pt)
CA (1) CA2537335C (pt)
DK (1) DK1734989T3 (pt)
ES (1) ES2384385T3 (pt)
GB (1) GB0322645D0 (pt)
IL (1) IL174464A (pt)
NO (1) NO340187B1 (pt)
NZ (1) NZ545661A (pt)
RU (1) RU2416426C2 (pt)
WO (1) WO2005030246A1 (pt)
ZA (1) ZA200601807B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2472737T3 (es) * 2006-04-27 2014-07-02 Lantmnnen As-Faktor Ab Usos m�dicos adicionales de la proteína antisecretora
PL2015767T3 (pl) * 2006-04-27 2016-05-31 Lantmaennen As Faktor Ab Zastosowanie czynnika przeciwwydzielniczego do leczenia nadciśnienia śródgałkowego
EP2037950B1 (en) * 2006-04-27 2014-04-23 Lantmännen AS-Faktor AB Further medical uses of antisecretory protein
AU2012201165B2 (en) * 2006-04-27 2013-12-19 Lantmannen As-Faktor Ab New approach to treat intraocular hypertension
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
EP3769778A1 (en) 2009-02-11 2021-01-27 Lantmännen Medical AB Use of antisecretory factors (af) for optimizing cellular uptake
ITMI20120008A1 (it) * 2012-01-04 2013-07-05 Biava Maura Composizioni ad attività anti-neurodegenerativa
US9738553B2 (en) * 2012-03-16 2017-08-22 Aquatech International, Llc Process for purification of produced water
AU2013263346B2 (en) * 2012-05-18 2018-08-23 The General Hospital Corporation Methods and compositions for treating amyloid deposits
US20190192622A1 (en) * 2012-12-20 2019-06-27 Lantmännen As-Faktor Ab Use of Antisecretory Factor (AF) in Glioblastoma Treatment
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
WO2018015379A1 (en) 2016-07-18 2018-01-25 Lantmännen As-Faktor Ab Antisecretory factor 17
US12582697B2 (en) 2018-06-28 2026-03-24 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2020065089A2 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted dehulled oat
WO2020065091A1 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted wheat
US20230096303A1 (en) * 2020-03-26 2023-03-30 Lantmännen Functional Foods Ab A Consumable Product Comprising Malted Cereals for Promoting Recovery at Physical Activity
CN112006035B (zh) * 2020-07-24 2021-07-30 江西新龙生物科技股份有限公司 用于防治植物病害的微生物源杀菌剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566455B1 (en) * 1995-06-07 2009-07-28 Gpc Biotech, Inc. E6AP-binding proteins
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
WO2001005968A1 (en) * 1999-06-21 2001-01-25 Inkine Pharmaceutical Company, Inc. Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
US20040072265A1 (en) * 2001-01-09 2004-04-15 Masahiro Toda Human glioma antigen and process for preparing the same
WO2003063688A2 (en) * 2002-01-25 2003-08-07 Incyte Corporation Protein modification and maintenance molecules

Also Published As

Publication number Publication date
AU2004275682B2 (en) 2010-01-28
IL174464A0 (en) 2006-08-01
US8748367B2 (en) 2014-06-10
IL174464A (en) 2015-08-31
KR101159858B1 (ko) 2012-06-25
CA2537335A1 (en) 2005-04-07
CN103028110B (zh) 2016-02-17
KR20060097718A (ko) 2006-09-14
CA2537335C (en) 2017-12-05
EP1734989B1 (en) 2012-03-21
ZA200601807B (en) 2007-06-27
EP1734989A1 (en) 2006-12-27
JP2007506735A (ja) 2007-03-22
NZ545661A (en) 2009-10-30
US20100286052A1 (en) 2010-11-11
US20070009575A1 (en) 2007-01-11
AU2004275682A1 (en) 2005-04-07
ES2384385T3 (es) 2012-07-04
CN103028110A (zh) 2013-04-10
GB0322645D0 (en) 2003-10-29
NO20060901L (no) 2006-06-20
DK1734989T3 (da) 2012-07-09
RU2416426C2 (ru) 2011-04-20
JP4943847B2 (ja) 2012-05-30
WO2005030246A1 (en) 2005-04-07
NO340187B1 (no) 2017-03-20
CN1856320A (zh) 2006-11-01
ATE550030T1 (de) 2012-04-15
RU2006114030A (ru) 2007-11-20

Similar Documents

Publication Publication Date Title
BRPI0414793A (pt) uso do fator anti-secretor
HUP0500477A2 (hu) Eljárások és készítmények embrionális és felnőttkori őssejtek támogatására stromasejtek alkalmazásával
WO2005046570A3 (en) Human stem cell materials and methods
WO2002060955A3 (en) Modified antibodies and methods of use
FI971955A7 (fi) Dopamineeristen solujen indusointi in vitro
DE60039752D1 (de) Herstellung tetravalenter antikörper
ATE322494T1 (de) Purin derivate, ihre herstellung und verwendung
WO2002064748A3 (en) Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
Jin et al. Amniotic epithelial cells promote wound healing in mice through high epithelialization and engraftment
Xu et al. Protective effects of leukemia inhibitory factor against oxidative stress during high glucose-induced apoptosis in podocytes
DE69930662D1 (de) Humane rezeptortyrosinkinase
Zhang et al. Knockout of p53 leads to a significant increase in ALV-J replication
WO2004043990A3 (en) Human stem cell materials and methods
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
MX2015013092A (es) Modificación y nuevas composiciones de proteínas secretoglobinas de humano.
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
WO2002090991A3 (en) Proteins and genes for diagnosis and treatment of erbb2-related cancer
Ghassemi et al. Novel media formulations to enhance chimeric antigen receptor (CAR) T-cell potency and anti-tumor cell function for adoptive immunotherapy
ATE415421T1 (de) Deamidiertes interferon-beta
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
Chao et al. Retinal ischemia: Therapeutic effects and mechanisms of paeoniflorin
ATE109509T1 (de) Anticoagulatorisches protein pp4-x, seine herstellung und verwendung.
WO2006119965A3 (en) Growth factor mutants with altered biological attributes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Ipc: A61K 38/17 (2006.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]